

Updates In Cognitive Impairment In Schizophrenia

Essay Submitted for Partial Fulfillment of
Master Degree in **Neuropsychiatry**

By
Ahmed Mohamed Ali Daabis
M.B.B.Ch

Under the supervision Of

Prof. Nahla El Sayed Nagy

*Professor of Psychiatry
Faculty of Medicine
Ain Shams University*

Prof. Nivert Zaki Hashim

*Professor of Psychiatry
Faculty of Medicine
Ain Shams University*

Dr. Mahmoud Mamdouh El Habiby

*Lecturer of Psychiatry
Faculty of Medicine
Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2014

ACKNOWLEDGMENT

*First and foremost I would like to thank my supervisor of this review, **Prof. Dr. Nahla El Sayed Nagy** Professor of psychiatry, Ain Shams University, for the valuable guidance and advice. She inspired me greatly to work in this essay. Her willingness to motivate me contributed tremendously to my review. I also would like to thank her for showing me some example that related to the topic of my essay. Besides, I would like to extend my warm appreciations and gratitude to **Prof. Dr. Nivert Zaki Hashim** Professor of psychiatry, Ain Shams University, for providing unfailingly excellent advice, supports, inspirations, criticisms, comments and suggestions contribute a valuable strength to make this review presentable and knowledgeable. Also, I would like to take this opportunity to*

*thank Dr. Mahmoud Mamdouh El Habiby
Lecturer of psychiatry, Ain Shams University, for
motivating me to do my best shot as well as for
his piece of advice on how I improve it and for his
assistance in organizing my review. In addition, I
would also like to thank to **my dear parents**, who
are supporting and tolerating me. Moreover, they
showed their love and gave me words of
encouragement that pushed me to do this well.
Finally, an honorable mention goes to **my wife** for
her understandings and supports on me in
completing this review. Without helps of the
particular that mentioned above, we would face
many difficulties while doing this.*

Ahmed Daabis

List of Contents

Item	Page No.
Acknowledgment	I
List of contents	III
List of tables	IV
List of figures	V
List of abbreviations	VII
Introduction and aim of work	1
Chapter 1: Diagnosis of schizophrenia according to DSM-5	7
Chapter 2: Cognitive functions	13
Chapter 3: Domains of cognitive impairment in schizophrenia	36
Chapter 4: Methods of assessment of cognition in schizophrenia	51
Chapter 5: Neuropathology of cognitive impairment associated with symptoms of schizophrenia	66
Chapter 6: Differential diagnosis from cognitive dysfunction in other psychiatric disorders	84
Chapter 7: Treatment of cognitive impairment in schizophrenia	102
Discussion	118
Summary	130
Recommendations	133
References	134
Arabic summary	

List of Tables

No.	Title (Description)	Page no.
1	Schizophrenia in DSM 5. Changes in diagnostic criteria from DSM-IV.	11
2	Distributed cognitive functions.	14
3	Localized cognitive functions.	15
4	Selected memory systems.	20
5	Definitions and neural basis of language functions	27
6	Neuropsychological tests for assessment of cognitive functions.	34
7	Cognitive deficits in schizophrenia with examples.	37
8	MATRICES consensus cognitive battery (MCCB).	54
9	Tests grouped by cognitive domain.	58
10	Factor loading for the multifactorial-6-factor model.	59
11	Comparison of z-scores on cognitive domains between patients and healthy controls.	60
12	Effect of antipsychotic drugs on cognition in schizophrenia.	105
13	Commonly Used Atypical Antipsychotic Medications Doses	111
14	Cognitive deficits in schizophrenia with examples and MATRICES consensus cognitive battery (MCCB).	121

List of Figures

No.	Title (Description)	Page no.
1	Performance of patients with schizophrenia on the BACS subtests and composite score standardized to healthy controls.	57
2	Standardization Sample's Mean T Scores on the Cognitive Domains of the MATRICS Consensus Cognitive Battery, by Age Group	62
3	Effect Size Comparing Neuropsychological Functioning in Males and Females schizophrenia patients	63
4	Standardization Sample's Mean T Scores on the Cognitive Domains of the MATRICS Consensus Cognitive Battery, by Gender	64
5	Standardization Sample's Mean T Scores on the Cognitive Domains of the MATRICS Consensus Cognitive Battery, by Educational Level	65
6	Brain regions involving neural circuitry disturbances in schizophrenia	69
7	Schematic illustration of putative functional alterations in DLPFC circuitry in schizophrenia.	72
8	Fractional anisotropy images; coronal, axial, and sagittal orientation.	80
9	Tract-based spatial statistics white matter skeleton superimposed on fractional anisotropy template; coronal, axial, and sagittal orientation.	81
10	Neuropsychological performance profile of schizophrenia, psychotic major depressive disorder, and psychotic bipolar disorder.	92
11	Comparison of Cognitive Performances of Patients with Alzheimer's disease, Depressive Disorder, or Normal Cognition to those with Late-Life Schizophrenia.	94

12	Profiles of neuropsychological performance of patient with schizophrenia in comparison to those with obsessive compulsive disorder.	98
13	changes in neurocognitive functions in patients treated with conventional and atypical antipsychotics for 14 weeks.	103
14	Receptor binding profiles of antipsychotic drugs. A larger pKi value represents a stronger affinity for the particular receptor	107
15	Mechanism for the ability of 5-HT _{1A} agonism to enhance cognitive function in subjects with schizophrenia.	113

List of Abbreviations

Abb.	Meaning
31P-MRS	Phosphorus magnetic resonance spectroscopy
AD	Alzheimer's disease
AD+P	Psychotic symptoms in Alzheimer disease
AI	Primary Auditory Cortex
APA	American Psychiatric Association
AV	Attention/Vigilance
BACS	Brief Assessment of Cognition in Schizophrenia
BPD	Borderline Personality Disorder
BVMT-R	Brief Visuospatial Memory Test—Revised
CATIE	The Clinical Antipsychotic Trials of Intervention Effectiveness
CIAS	Cognitive impairment associated with schizophrenia
CPT	Continuous Performance Test
CPT-IP	Continuous Performance Test-Identical Pairs
D2	Dopamine Receptor 2
DA	Dopamine
DLPFC	The Dorsolateral Prefrontal Cortex
DS-CPT	Degraded Stimulus-Continuous Performance Test
DSM	Diagnostic and Statistical Manual of mental disorders
DTI	Diffusion Tensor Imaging
EEG	Electroencephalograms
EUFAST	The European Union First Episode Schizophrenia Trial
FA	Fractional anisotropy
fMRI	Functional Magnetic Resonance Imaging
GABA	Gamma Aminobutyric Acid
HG	Heschl's gyrus
HVLT-R	Hopkins Verbal Learning Test—Revised

K-AVLT	Korean version of Auditory Verbal Learning Test
K-CFT	Korean version of Complex Figure Test
K-WAIS	Korean version of Wechsler Adult Inelegance Scale
LLS	late-life schizophrenia
MATRICES	The Measurement and Treatment Research to Improve Cognition in Schizophrenia
MCCB	The MATRICS Consensus Cognitive Battery
MD	Mean diffusivity
MSCEIT	Mayer-Salovey-Caruso Emotional Intelligence Test
MTI	Magnetization Transfer Imaging
MTR	Magnetization Transfer Ratio
NAB	Neuropsychological Assessment Battery
NIMH	The National Institute of Mental Health
NMDA	N-Methyl-D-Aspartate
OC	obsessive-compulsive
OCD	obsessive-compulsive disorder
PET	Positron emission tomography
RAVLT	Rey Auditory Verbal Learning Test
ROI	region of interest
RP	Reasoning/Problem solving
sMRI	Structural Magnetic Resonance Imaging
SP	Speed of processing
VBA	voxel-based analysis
VM	Verbal learning and memory
VSM	Visual learning and memory
WAIS-R	Wechsler Adult Inelegance Scale-Revised
WM	Working memory
WMS-III	Wechsler Memory Scale—3rd Ed.

INTRODUCTION

The DSM -5 describes Schizophrenia in terms of a severe, chronic, and potentially disabling thought disorder (**American Psychiatric Association 2013**). The prevalence of schizophrenia is about one percent of the general population (**APA 2013**). It is the most common chronic psychosis in Egypt (**Okasha et al., 1993**).

It has a robust genetic component, tends to appear during young adulthood, and is typically marked by periods of remission and relapse throughout the lifespan. Lack of medication compliance is a primary reason for relapse (**Battaglia 2014**). It most commonly manifests itself as auditory hallucinations, paranoid delusions, or disorganized speech and thinking, and it is accompanied by significant social or occupational dysfunction. The onset of symptoms typically occurs in young adulthood (**Van Os. and Kapur 2009**). Diagnosis is based on observed behavior and the patient's reported experiences.

Despite the etymology of the term from the Greek roots *skhizein* (to split) and *phrēn* (mind), schizophrenia does not imply a "split personality", or "multiple personality disorder" (which is known these days as dissociative identity disorder) a condition with which it is often confused in public perception (**Picchioni**

and Murray 2007). Rather, the term means a "splitting of mental functions", because of the symptomatic presentation of the illness.

The disorder is thought mainly to affect cognition, but it also usually contributes to chronic problems with behavior and emotion. People with schizophrenia are likely to have additional (comorbid) conditions, including major depression and anxiety disorders; the lifetime occurrence of substance abuse is almost 50% (**Buckley et al., 2009**). Social problems, such as long-term unemployment, poverty and homelessness, are common. The average life expectancy of people with the disorder is 12 to 15 years less than those without, the result of increased physical health problems and a higher suicide rate (about 5%) (**Van Os. and Kapur 2009**). The larger literature examining the association between severity of cognitive deficits and psychopathologic symptoms is consistent in showing a significant but modest association between severity of cognitive deficits and negative symptoms, but no association between cognitive deficits and positive symptoms, such as hallucinations and delusions (**de Gracia et al., 2009**).

Cognitive performance deficits in schizophrenia have been identified in almost every measurable cognitive ability domain, from basic sensory and perceptual functions through preconscious information processing and early attention to higher order

cognition, including selective and sustained attention, working memory, episodic memory in verbal and nonverbal domains, processing speed, and problem solving (**Heinrichs et al., 1998; Dickinson et al., 2007**).

Cognitive performance deficits are seen in high-risk groups prior to the onset of psychotic illness (**Erlenmeyer-Kimling et al., 2000**).

Deficits are broadly evident and well established at first episode and remain fairly stable through middle age (**Albus et al., 2002; Hughes et al., 2003**), but there is evidence of exacerbation of deficits in later life (**Friedman et al., 2001**), perhaps due to the duration of initially untreated psychosis (**Waddington et al., 1995**).

Studies using neuropsychological tests and brain imaging technologies such as fMRI and PET to examine functional differences in brain activity have shown that differences seem to most occur in the frontal lobes, hippocampus and temporal lobes (**Kircher et al., 2006**).these differences have been linked to the neurocognitive deficits often associated with schizophrenia (**Green 2006**).

There are also frequent abnormalities in the size or shape of the corpus callosum (**Price et al., 2007; Walterfang et al., 2008**), supporting the view of schizophrenia as a disconnection syndrome (**Friston and Frith 1995**) and, as with earlier CT

findings, there are enlarged ventricles (**DeLisi 2008; Shenton et al., 2001**). Functional imaging studies have found lower activity in the prefrontal cortex and abnormal activation in the temporal lobes during performance of both verbal and visual tasks (**Eyler et al., 2004, 2008; Keshavan et al., 2008**).

The white matter findings of **Wexler et al. (2009)**, suggested abnormalities of functional connectivity in participants with schizophrenia and cognitive impairment, but not in healthy controls or participants with schizophrenia and no cognitive impairment.

Because these cognitive deficits have been linked to poor functional outcome (**Green et al., 1996; Niendam et al., 2006**), there is considerable interest in developing treatments for cognitive impairments.

Until recently, antipsychotic drug development in schizophrenia has focused mainly on developing drugs that reduce the positive symptoms of schizophrenia (**Miyamoto et al., 2005**). In a recent meta-analysis, patients treated with typical antipsychotics were actually shown to have small but detectable improvements in several cognitive domains (**Mishara et al., 2004**); In addition, there is some evidence for the superiority of atypical antipsychotics, such as olanzapine and risperidone, over typicals in improving cognitive performance (**Bilder et al., 2002 ; Purdon et al., 2000**).

In recent years, there has been an increasing recognition of the need for psychosocial rehabilitative interventions for schizophrenia (**Insel 2009**). In that regard, recent efforts to develop cognitive training programs for schizophrenia offer promise (**Twamley et al., 2003; Velligan et al. 2006**).

AIM OF THE WORK

- 1- Clarification of domains of cognitive impairment in schizophrenia.
- 2- Focusing on neuropathology of cognitive impairment associated with symptoms of schizophrenia.
- 3- Differential diagnosis from cognitive dysfunction in other psychiatric disorders.
- 4- Highlighting methods of assessment of cognition in schizophrenia.
- 5- Focusing on special considerations in treatment of cognitive impairment in schizophrenia.